* Akoya Biosciences Inc AKYA.OQ reported a quarterly
adjusted
loss of 48 cents per share for the quarter ended in January,
higher than the same quarter last year, when the company
reported EPS of -49 cents. The mean expectation of
eight analysts for the quarter was for a loss of 29 cents per
share. Wall Street expected results to range from -32 cents
to -26 cents per share.
* Revenue fell 14.3% to $18.35 million from a year ago;
analysts
expected $24.28 million.
* Akoya Biosciences Inc's reported EPS for the quarter was a
loss
of 48 cents.
* The company reported a quarterly loss of $23.48 million.
* Akoya Biosciences Inc shares had fallen by 9.1% this
quarter and
lost 12.6% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by
about 12.3%
in the last three months.
* In the last 30 days, one analyst negatively revised an
earnings
estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the advanced
medical
equipment & technology peer group is also "buy"
Wall Street's median 12-month price target for Akoya Biosciences
Inc is $8.50
This summary was machine generated from LSEG data May 13 at
09:22 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Mar. 31 2024 -0.29 -0.48 Missed
Dec. 31 2023 -0.27 -0.22 Beat
Sep. 30 2023 -0.37 -0.26 Beat
Jun. 30 2023 -0.44 -0.46 Missed